

Lioe-Fee de Geus-Oei

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8051043/publications.pdf>

Version: 2024-02-01

193
papers

7,546
citations

81900

39
h-index

62596

80
g-index

199
all docs

199
docs citations

199
times ranked

11855
citing authors

#	ARTICLE	IF	CITATIONS
1	2-[18F]FDG PET/CT in Fever of Unknown Origin. , 2022, , 209-216.		0
2	Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1386-1406.	6.4	24
3	Prospective evaluation of percutaneous hepatic perfusion with melphalan as a treatment for unresectable liver metastases from colorectal cancer. PLoS ONE, 2022, 17, e0261939.	2.5	2
4	[18F]FDG-PET/CT to prevent futile surgery in indeterminate thyroid nodules: a blinded, randomised controlled multicentre trial. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1970-1984.	6.4	22
5	Perspective paper about the joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG-PET/CT external beam radiation treatment planning in lung cancer. Radiotherapy and Oncology, 2022, 168, 37-39.	0.6	4
6	Quantitative classification and radiomics of [18F]FDG-PET/CT in indeterminate thyroid nodules. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2174-2188.	6.4	19
7	Design and evaluation of a modular multimodality imaging phantom to simulate heterogeneous uptake and enhancement patterns for radiomic quantification in hybrid imaging: A feasibility study. Medical Physics, 2022, 49, 3093-3106.	3.0	2
8	Nuclear medicine imaging methods of radiation-induced cardiotoxicity. Seminars in Nuclear Medicine, 2022, 52, 597-610.	4.6	9
9	The Value of 18F-FDG-PET-CT Imaging in Treatment Evaluation of Colorectal Liver Metastases: A Systematic Review. Diagnostics, 2022, 12, 715.	2.6	4
10	Intraoperative Near-Infrared Fluorescence Imaging with Indocyanine Green for Identification of Gastrointestinal Stromal Tumors (GISTs), a Feasibility Study. Cancers, 2022, 14, 1572.	3.7	2
11	A new colleague in nuclear medicine, the clinical technologist: quo vadis?. European Journal of Nuclear Medicine and Molecular Imaging, 2022, , 1.	6.4	2
12	Brain Inflammation and Intracellular α -Synuclein Aggregates in Macaques after SARS-CoV-2 Infection. Viruses, 2022, 14, 776.	3.3	23
13	FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3452-3469.	6.4	9
14	Study Protocol: Adjuvant Holmium-166 Radioembolization After Radiofrequency Ablation in Early-Stage Hepatocellular Carcinoma Patientsâ€™A Dose-Finding Study (HORA EST HCC Trial). CardioVascular and Interventional Radiology, 2022, 45, 1057-1063.	2.0	4
15	SNMMI Procedure Standard/EANM Practice Guideline for Molecular Breast Imaging with Dedicated 67 Ge-Cameras. Journal of Nuclear Medicine Technology, 2022, 50, 103-110.	0.8	10
16	Health-related quality of life following FDG-PET/CT for cytological indeterminate thyroid nodules. Endocrine Connections, 2022, 11, .	1.9	4
17	Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study. Annals of Surgical Oncology, 2021, 28, 1130-1141.	1.5	19
18	Maximizing the potency of oxaliplatin coated nanoparticles with folic acid for modulating tumor progression in colorectal cancer. Materials Science and Engineering C, 2021, 120, 111678.	7.3	14

#	ARTICLE	IF	CITATIONS
19	Cell-Based Tracers as Trojan Horses for Image-Guided Surgery. International Journal of Molecular Sciences, 2021, 22, 755.	4.1	9
20	Striatal dopamine synthesis capacity in autism spectrum disorder and its relation with social defeat: an [18F]-FDOPA PET/CT study. Translational Psychiatry, 2021, 11, 47.	4.8	16
21	Denosumab Reduces Lesional Fluoride Skeletal Burden on Na[18F]F PET-CT in Patients With Fibrous Dysplasia/McCune-Albright Syndrome. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2980-e2994.	3.6	14
22	Radioiodine in Differentiated Thyroid Carcinoma: Do We Need Diagnostic Pre-Ablation Iodine-123 Scintigraphy to Optimize Treatment?. Diagnostics, 2021, 11, 553.	2.6	1
23	Personalising sarcoma care using quantitative multimodality imaging for response assessment. Clinical Radiology, 2021, 76, 313.e1-313.e13.	1.1	7
24	Endoglin/CD105-Based Imaging of Cancer and Cardiovascular Diseases: A Systematic Review. International Journal of Molecular Sciences, 2021, 22, 4804.	4.1	10
25	Global cardiac sympathetic denervation is associated with diffuse myocardial fibrosis in non-ischemic cardiomyopathy. Europace, 2021, 23, .	1.7	0
26	Sympathetic innervation pattern in NICM patients with ventricular tachycardia -anteroseptal versus inferolateral substrates-. Europace, 2021, 23, .	1.7	0
27	Experimental validation of absolute SPECT/CT quantification for response monitoring in patients with coronary artery disease. EJNMMI Physics, 2021, 8, 48.	2.7	2
28	The Influence of the Exclusion of Central Necrosis on [18F]FDG PET Radiomic Analysis. Diagnostics, 2021, 11, 1296.	2.6	6
29	Nanocarriers as a Tool for the Treatment of Colorectal Cancer. Pharmaceutics, 2021, 13, 1321.	4.5	13
30	“PET/CT Variants and Pitfalls in Lung Cancer and Mesothelioma” Seminars in Nuclear Medicine, 2021, 51, 458-473.	4.6	8
31	Incorporating radiomics into clinical trials: expert consensus endorsed by the European Society of Radiology on considerations for data-driven compared to biologically driven quantitative biomarkers. European Radiology, 2021, 31, 6001-6012.	4.5	53
32	18F-FDG-PET/CT imaging in fever and inflammation of unknown origin. , 2021, , .		0
33	Early response evaluation using 18F-FDG-PET/CT does not influence management of patients with metastatic gastrointestinal stromal tumors (GIST) treated with palliative intent. Nuklearmedizin - Nuclear Medicine, 2021, 60, 411-416.	0.7	1
34	Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography. Frontiers in Oncology, 2021, 11, 772530.	2.8	14
35	Diagnostics in Patients Suspect for Breast Cancer in The Netherlands. Current Oncology, 2021, 28, 4998-5008.	2.2	0
36	Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy. Cancers, 2021, 13, 6088.	3.7	8

#	ARTICLE	IF	CITATIONS
37	Molecular Targeted Positron Emission Tomography Imaging and Radionuclide Therapy of Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2021, 13, 6164.	3.7	8
38	Cerebral [18F]-FDOPA Uptake in Autism Spectrum Disorder and Its Association with Autistic Traits. <i>Diagnostics</i> , 2021, 11, 2404.	2.6	6
39	Prognostic Value of Quantitative [18F]FDG-PET Features in Patients with Metastases from Soft Tissue Sarcoma. <i>Diagnostics</i> , 2021, 11, 2271.	2.6	3
40	Limited clinical value of two consecutive post-transplant renal scintigraphy procedures. <i>European Radiology</i> , 2020, 30, 452-460.	4.5	5
41	Can [18F]F-FDG PET/CT be used to assess the pre-operative extent of peritoneal carcinomatosis in patients with colorectal cancer?. <i>Abdominal Radiology</i> , 2020, 45, 301-306.	2.1	13
42	Lymphoscintigraphy and sentinel lymph node biopsy in vulvar carcinoma: update from a European expert panel. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1261-1274.	6.4	32
43	Quantifying skeletal burden in fibrous dysplasia using sodium fluoride PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1527-1537.	6.4	17
44	Near-infrared fluorescence imaging compared to standard sentinel lymph node detection with blue dye in patients with vulvar cancer – a randomized controlled trial. <i>Gynecologic Oncology</i> , 2020, 159, 672-680.	1.4	26
45	Adding the temporal domain to PET radiomic features. <i>PLoS ONE</i> , 2020, 15, e0239438.	2.5	12
46	Cholesterol-functionalized carvedilol-loaded PLGA nanoparticles: anti-inflammatory, antioxidant, and antitumor effects. <i>Journal of Nanoparticle Research</i> , 2020, 22, 1.	1.9	5
47	Effect of Oxaliplatin-Loaded Poly (d,l-Lactide-co-Glycolic Acid) (PLGA) Nanoparticles Combined with Retinoic Acid and Cholesterol on Apoptosis, Drug Resistance, and Metastasis Factors of Colorectal Cancer. <i>Pharmaceutics</i> , 2020, 12, 193.	4.5	25
48	Considerations on bone volume normalization in quantifying skeletal burden in fibrous dysplasia using sodium fluoride PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1351-1352.	6.4	1
49	Twelve weeks of exenatide treatment increases [18F]fluorodeoxyglucose uptake by brown adipose tissue without affecting oxidative resting energy expenditure in nondiabetic males. <i>Metabolism: Clinical and Experimental</i> , 2020, 106, 154167.	3.4	23
50	Lifestyle-Intervention-Induced Reduction of Abdominal Fat Is Reflected by a Decreased Circulating Glycerol Level and an Increased HDL Diameter. <i>Molecular Nutrition and Food Research</i> , 2020, 64, e1900818.	3.3	6
51	Nuclear Medicine Imaging of Fever of Unknown Origin. , 2020, , 199-211.		1
52	Nuclear medicine radiomics in precision medicine: why we can't do without artificial intelligence. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 278-290.	0.7	9
53	Targeting Glycans and Heavily Glycosylated Proteins for Tumor Imaging. <i>Cancers</i> , 2020, 12, 3870.	3.7	13
54	Nuclear medicine in precision oncology: a foreword. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 231-233.	0.7	0

#	ARTICLE	IF	CITATIONS
55	Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 250-264.	0.7	4
56	Evaluation of FDG-PET/CT Use in Children with Suspected Infection or Inflammation. Diagnostics, 2020, 10, 715.	2.6	4
57	Adding the temporal domain to PET radiomic features. , 2020, 15, e0239438.		0
58	Adding the temporal domain to PET radiomic features. , 2020, 15, e0239438.		0
59	Adding the temporal domain to PET radiomic features. , 2020, 15, e0239438.		0
60	Adding the temporal domain to PET radiomic features. , 2020, 15, e0239438.		0
61	Radiomics in Vulvar Cancer: First Clinical Experience Using ¹⁸ F-FDG PET/CT Images. Journal of Nuclear Medicine, 2019, 60, 199-206.	5.0	22
62	Optimal respiratory-gated [18F]FDG PET/CT significantly impacts the quantification of metabolic parameters and their correlation with overall survival in patients with pancreatic ductal adenocarcinoma. EJNMMI Research, 2019, 9, 24.	2.5	7
63	Quantitative Volumetric Assessment of Ablative Margins in Hepatocellular Carcinoma: Predicting Local Tumor Progression Using Nonrigid Registration Software. Journal of Oncology, 2019, 2019, 1-8.	1.3	14
64	PET imaging during hypoglycaemia to study adipose tissue metabolism. European Journal of Clinical Investigation, 2019, 49, e13120.	3.4	3
65	Early Metabolic Response as a Predictor of Treatment Outcome in Patients With Metastatic Soft Tissue Sarcomas. Anticancer Research, 2019, 39, 1309-1316.	1.1	8
66	Cardiac molecular pathways influenced by doxorubicin treatment in mice. Scientific Reports, 2019, 9, 2514.	3.3	22
67	Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systemsâ€™ Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial. CardioVascular and Interventional Radiology, 2019, 42, 841-852.	2.0	28
68	Intramyocardial bone marrow cell injection does not lead to functional improvement in patients with chronic ischaemic heart failure without considerable ischaemia. Netherlands Heart Journal, 2019, 27, 81-92.	0.8	3
69	Embolization of variant hepatic arteries in patients undergoing percutaneous hepatic perfusion for unresectable liver metastases from ocular melanoma. Diagnostic and Interventional Radiology, 2019, 25, 451-458.	1.5	7
70	Improving the Spatial Alignment in PET/CT Using Amplitude-Based Respiration-Gated PET and Patient-Specific Breathingâ€™Instructed CT. Journal of Nuclear Medicine Technology, 2019, 47, 154-159.	0.8	2
71	Metabolic Subtyping of Pheochromocytoma and Paraganglioma by ¹⁸ F-FDG Pharmacokinetics Using Dynamic PET/CT Scanning. Journal of Nuclear Medicine, 2019, 60, 745-751.	5.0	21
72	The role of proportionate kinetic growth rate fraction in future remnant liver function over volume determined by 99mTc-Mebrofenin hepatobiliary scintigraphy including SPECT and computed tomography in the risk prediction of postoperative mortality in ALPPS. Surgery, 2019, 165, 1244-1245.	1.9	0

#	ARTICLE	IF	CITATIONS
73	Long-term prognostic value of single-photon emission computed tomography myocardial perfusion imaging after primary PCI for STEMI. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 1287-1293.	1.2	8
74	Diagnostic Utility of Molecular and Imaging Biomarkers in Cytological Indeterminate Thyroid Nodules. <i>Endocrine Reviews</i> , 2018, 39, 154-191.	20.1	45
75	Experimental validation of absolute SPECT/CT quantification for response monitoring in breast cancer. <i>Medical Physics</i> , 2018, 45, 2143-2153.	3.0	25
76	The clinical impact of molecular breast imaging in women with proven invasive breast cancer scheduled for breast-conserving surgery. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 513-522.	2.5	5
77	Modalities for image- and molecular-guided cancer surgery. <i>British Journal of Surgery</i> , 2018, 105, e69-e83.	0.3	29
78	The diagnostic value of ¹⁸ F-FDG-PET/CT and MRI in suspected vertebral osteomyelitis – a prospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 798-805.	6.4	67
79	Fluorescence- and multispectral optoacoustic imaging for an optimized detection of deeply located tumors in an orthotopic mouse model of pancreatic carcinoma. <i>International Journal of Cancer</i> , 2018, 142, 2118-2129.	5.1	8
80	The Value of ¹⁸ F-FDG PET/CT in Diagnosis and During Follow-up in 273 Patients with Chronic Q Fever. <i>Journal of Nuclear Medicine</i> , 2018, 59, 127-133.	5.0	26
81	Is Technetium-99m Sestamibi Imaging Able to Predict Pathologic Nonresponse to Neoadjuvant Chemotherapy in Breast Cancer? A Meta-analysis Evaluating Current Use and Shortcomings. <i>Clinical Breast Cancer</i> , 2018, 18, 9-18.	2.4	15
82	Early Evaluation of Response Using ¹⁸ F-FDG PET Influences Management in Gastrointestinal Stromal Tumor Patients Treated with Neoadjuvant Imatinib. <i>Journal of Nuclear Medicine</i> , 2018, 59, 194-196.	5.0	24
83	Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. <i>Targeted Oncology</i> , 2018, 13, 641-648.	3.6	10
84	External validation of an NTCP model for acute esophageal toxicity in locally advanced NSCLC patients treated with intensity-modulated (chemo-)radiotherapy. <i>Radiotherapy and Oncology</i> , 2018, 129, 249-256.	0.6	8
85	Stereotactic radiotherapy boost after definite chemoradiation for non-responding locally advanced NSCLC based on early response monitoring ¹⁸ F-FDG-PET/CT. <i>Physics and Imaging in Radiation Oncology</i> , 2018, 7, 16-22.	2.9	4
86	¹⁸ F-fluorodeoxyglucose positron-emission tomography combined with computed tomography as a diagnostic tool in native valve endocarditis. <i>Nuclear Medicine Communications</i> , 2018, 39, 747-752.	1.1	37
87	Effect of sitagliptin on energy metabolism and brown adipose tissue in overweight individuals with prediabetes: a randomised placebo-controlled trial. <i>Diabetologia</i> , 2018, 61, 2386-2397.	6.3	19
88	¹⁸ F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) – A prospective externally validated study. <i>PLoS ONE</i> , 2018, 13, e0192859.	2.5	57
89	Early metabolic response as predictor for treatment outcome of pazopanib in patients with metastatic soft tissue sarcomas (the PREDICT study).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11555-11555.	1.6	2
90	Can transplant renal scintigraphy predict the duration of delayed graft function? A dual center retrospective study. <i>PLoS ONE</i> , 2018, 13, e0193791.	2.5	15

#	ARTICLE	IF	CITATIONS
91	Image-guided adaptive radiotherapy in patients with locally advanced non-small cell lung cancer: the art of PET. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2018, 62, 369-384.	0.7	6
92	Novel frontiers of dedicated molecular imaging in breast cancer diagnosis. Translational Cancer Research, 2018, 7, S295-S306.	1.0	3
93	Everolimus exposure and early metabolic response as predictors for treatment outcomes in breast cancer patients treated with everolimus and exemestane.. Journal of Clinical Oncology, 2018, 36, 1062-1062.	1.6	0
94	A comparison of the diagnostic value of MRI and 18F-FDG-PET/CT in suspected spondylodiscitis. Infection, 2017, 45, 41-49.	4.7	90
95	Metal Artifact Reduction of CT Scans to Improve PET/CT. Journal of Nuclear Medicine, 2017, 58, 1867-1872.	5.0	29
96	Tumor Delineation and Quantitative Assessment of Glucose Metabolic Rate within Histologic Subtypes of Non-Small Cell Lung Cancer by Using Dynamic ¹⁸ F Fluorodeoxyglucose PET. Radiology, 2017, 283, 547-559.	7.3	16
97	Inclusion of Incidental Radiation Dose to the Cardiac Atria and Ventricles Does Not Improve the Prediction of Radiation Pneumonitis in Advanced-Stage Non-Small Cell Lung Cancer Patients Treated With Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 99, 434-441.	0.8	16
98	¹⁸ F-FDG PET/CT Optimizes Treatment in <i>Staphylococcus Aureus</i> Bacteremia and Is Associated with Reduced Mortality. Journal of Nuclear Medicine, 2017, 58, 1504-1510.	5.0	70
99	Diagnostic delay in primary osteosarcoma (OST) and Ewing sarcoma (ES) of bone in relation to metabolic activity on FDG PET/CT. European Journal of Cancer, 2017, 72, S153.	2.8	1
100	First Clinical Experience Using Stereotactic Breast Biopsy Guided by 99mTc-Sestamibi. American Journal of Roentgenology, 2017, 209, 1367-1373.	2.2	17
101	The Predictive Value of Early In-Treatment ¹⁸ F-FDG PET/CT Response to Chemotherapy in Combination with Bevacizumab in Advanced Nonsquamous Non-Small Cell Lung Cancer. Journal of Nuclear Medicine, 2017, 58, 1243-1248.	5.0	13
102	Comparison of toxicity and outcome in advanced stage non-small cell lung cancer patients treated with intensity-modulated (chemo-)radiotherapy using IMRT or VMAT. Radiotherapy and Oncology, 2017, 122, 295-299.	0.6	31
103	PV-0372: Histology-specific quantitative mapping and targeting of glucose and glutamine metabolism in NSCLC. Radiotherapy and Oncology, 2017, 123, S200-S201.	0.6	0
104	Evaluation of EphA2 and EphB4 as Targets for Image-Guided Colorectal Cancer Surgery. International Journal of Molecular Sciences, 2017, 18, 307.	4.1	14
105	PET-guided treatment algorithms in oesophageal cancer: the promise of the near future!. Journal of Thoracic Disease, 2017, 9, 2736-2739.	1.4	5
106	Fludeoxyglucose positron emission tomography-computed tomography scan showing polyarthritis in a patient with an atypical presentation of Henoch-Schönlein vasculitis without clinical signs of arthritis: a case report. Journal of Medical Case Reports, 2016, 10, 159.	0.8	4
107	¹⁸ F-FDG PET/CT in Detecting Metastatic Infection in Children. Clinical Nuclear Medicine, 2016, 41, 278-281.	1.3	6
108	From Incidentaloma to Oncocytoma: A Role for Hybrid Molecular Imaging in Characterising Renal Masses?. European Urology, 2016, 69, 417-418.	1.9	1

#	ARTICLE	IF	CITATIONS
109	Comparison of Tumor Uptake Heterogeneity Characterization Between Static and Parametric ¹⁸ F-FDG PET Images in Non-Small Cell Lung Cancer. Journal of Nuclear Medicine, 2016, 57, 1033-1039.	5.0	31
110	Positron emission tomography response criteria in solid tumours criteria for quantitative analysis of [¹⁸ F]-fluorodeoxyglucose positron emission tomography with integrated computed tomography for treatment response assessment in metastasised solid tumours: All that glitters is not gold. European Journal of Cancer, 2016, 56, 54-58.	2.8	9
111	Performance of automatic image segmentation algorithms for calculating total lesion glycolysis for early response monitoring in non-small cell lung cancer patients during concomitant chemoradiotherapy. Radiotherapy and Oncology, 2016, 119, 473-479.	0.6	17
112	EP-1851: Quantitative assessment of glucose metabolic rate within NSCLC histologies using dynamic ¹⁸ F-FDG PET. Radiotherapy and Oncology, 2016, 119, S871.	0.6	0
113	PO-0919: Optimal respiratory gated FDG-PET for characterizing intra-tumour heterogeneity in lung cancer. Radiotherapy and Oncology, 2016, 119, S445.	0.6	0
114	The Impact of Optimal Respiratory Gating and Image Noise on Evaluation of Intratumor Heterogeneity on ¹⁸ F-FDG PET Imaging of Lung Cancer. Journal of Nuclear Medicine, 2016, 57, 1692-1698.	5.0	67
115	Performance of 3DOSEM and MAP algorithms for reconstructing low count SPECT acquisitions. Zeitschrift Fur Medizinische Physik, 2016, 26, 311-322.	1.5	10
116	Does diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA). Journal of Nuclear Cardiology, 2016, 23, 824-832.	2.1	29
117	Evaluating the use of optimally respiratory gated ¹⁸ F-FDG-PET in target volume delineation and its influence on radiation doses to the organs at risk in non-small-cell lung cancer patients. Nuclear Medicine Communications, 2016, 37, 66-73.	1.1	8
118	Update on F-18-fluoro-deoxy-glucose-PET/computed tomography in nonsmall cell lung cancer. Current Opinion in Pulmonary Medicine, 2015, 21, 314-321.	2.6	20
119	Multimodality Imaging to Predict Response to Systemic Treatment in Patients with Advanced Colorectal Cancer. PLoS ONE, 2015, 10, e0120823.	2.5	33
120	New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide. Biomarkers, 2015, 20, 143-148.	1.9	47
121	Improving the Spatial Alignment in PET/CT Using Amplitude-Based Respiration-Gated PET and Respiration-Trigged CT. Journal of Nuclear Medicine, 2015, 56, 1817-1822.	5.0	20
122	PET in the management of locally advanced and metastatic NSCLC. Nature Reviews Clinical Oncology, 2015, 12, 395-407.	27.6	75
123	Multivariable normal-tissue complication modeling of acute esophageal toxicity in advanced stage non-small cell lung cancer patients treated with intensity-modulated (chemo-)radiotherapy. Radiotherapy and Oncology, 2015, 117, 49-54.	0.6	55
124	The impact of respiratory gated positron emission tomography on clinical staging and management of patients with lung cancer. Lung Cancer, 2015, 90, 217-223.	2.0	19
125	Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients. Cancer Chemotherapy and Pharmacology, 2015, 76, 957-967.	2.3	25
126	Abstract OT3-2-01: IMPACT: IMaging PATients for Cancer drug selecTion - Metastatic breast cancer (MBC)., 2015, .		4

#	ARTICLE	IF	CITATIONS
127	Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer. Anticancer Research, 2015, 35, 5601-6.	1.1	2
128	Amplitude-based optimal respiratory gating in positron emission tomography in patients with primary lung cancer. European Radiology, 2014, 24, 3242-3250.	4.5	51
129	High Performance of ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography and Contrast-Enhanced CT in a Rapid Outpatient Diagnostic Program for Patients with Suspected Lung Cancer. Respiration, 2014, 87, 32-37.	2.6	2,816
130	Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model. Contrast Media and Molecular Imaging, 2014, 9, 237-245.	0.8	24
131	In-treatment assessment of response in locally advanced NSCLC: Paving the way for personalized medicine. Lung Cancer, 2014, 86, 374.	2.0	0
132	Comparison of a Free-Breathing CT and an Expiratory Breath-Hold CT with Regard to Spatial Alignment of Amplitude-Based Respiratory-Gated PET and CT Images. Journal of Nuclear Medicine Technology, 2014, 42, 269-273.	0.8	13
133	Glucose Metabolism in NSCLC Is Histology-Specific and Diverges the Prognostic Potential of 18FDG-PET for Adenocarcinoma and Squamous Cell Carcinoma. Journal of Thoracic Oncology, 2014, 9, 1485-1493.	1.1	107
134	Avastin Scintigraphy in Surveillance of Bevacizumab Treatment in a Patient With Neurofibromatosis Type 2. Clinical Nuclear Medicine, 2014, 39, 277-280.	1.3	2
135	Comparison of liver SUV using unenhanced CT versus contrast-enhanced CT for attenuation correction in 18F-FDG PET/CT. Nuclear Medicine Communications, 2014, 35, 472-477.	1.1	7
136	Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT. Targeted Oncology, 2014, 9, 339-347.	3.6	28
137	Diagnostic value of FDG-PET/(CT) in children with fever of unknown origin and unexplained fever during immune suppression. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1916-1923.	6.4	33
138	Early myocardial deformation abnormalities in breast cancer survivors. Breast Cancer Research and Treatment, 2014, 146, 127-135.	2.5	12
139	Cost-Effectiveness of FDG-PET/CT for Cytologically Indeterminate Thyroid Nodules: A Decision Analytic Approach. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3263-3274.	3.6	47
140	Immunotherapy response evaluation with 18F-FDG-PET in patients with advanced stage renal cell carcinoma. World Journal of Urology, 2013, 31, 841-846.	2.2	13
141	Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: a functional imaging approach. Investigational New Drugs, 2013, 31, 881-890.	2.6	7
142	¹⁸ F-FDG PET Early Response Evaluation of Locally Advanced Non-Small Cell Lung Cancer Treated with Concomitant Chemoradiotherapy. Journal of Nuclear Medicine, 2013, 54, 1528-1534.	5.0	104
143	Nodular Fasciitis on 18F-FDG PET. Clinical Nuclear Medicine, 2013, 38, 442-443.	1.3	2
144	Catecholamines influence myocardial 123I MIBG uptake in neuroblastoma patients. Nuklearmedizin - Nuclear Medicine, 2013, 52, 228-234.	0.7	1

#	ARTICLE	IF	CITATIONS
145	False Positive 18F-FDG PET/CT Due to Inflamed Concha Bullosa. Clinical Nuclear Medicine, 2012, 37, 509-510.	1.3	3
146	Quantitative Assessment of Heterogeneity in Tumor Metabolism Using FDG-PET. International Journal of Radiation Oncology Biology Physics, 2012, 82, e725-e731.	0.8	35
147	Tumour response prediction by diffusion-weighted MR imaging: Ready for clinical use?. Critical Reviews in Oncology/Hematology, 2012, 83, 194-207.	4.4	61
148	Timeliness of lung cancer diagnosis and treatment in a rapid outpatient diagnostic program with combined 18FDG-PET and contrast enhanced CT scanning. Lung Cancer, 2012, 75, 336-341.	2.0	42
149	Differences in metabolism between adeno- and squamous cell non-small cell lung carcinomas: Spatial distribution and prognostic value of GLUT1 and MCT4. Lung Cancer, 2012, 76, 316-323.	2.0	99
150	Reproducibility of functional volume and activity concentration in 18F-FDG PET/CT of liver metastases in colorectal cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1858-1867.	6.4	24
151	Treatment outcome and toxicity of intensity-modulated (chemo) radiotherapy in stage III non-small cell lung cancer patients. Radiation Oncology, 2012, 7, 150.	2.7	33
152	Hybrid 18F-FDG PET/CT of colonic anastomosis. Nuklearmedizin - NuclearMedicine, 2012, 51, 252-256.	0.7	2
153	FDG-PET/CT based response-adapted treatment. Cancer Imaging, 2012, 12, 324-335.	2.8	17
154	Letter to the Editor: Interobserver Variability of Heart-to-Mediastinum Ratio in I-123 MIBG Sympathetic Imaging. Current Cardiology Reports, 2012, 14, 389-390.	2.9	3
155	EUS-FNA for the detection of left adrenal metastasis in patients with lung cancer. Lung Cancer, 2011, 73, 310-315.	2.0	61
156	Vascular and Metabolic Response to Bevacizumab-Containing Regimens in Two Patients With Colorectal Liver Metastases Measured by Dynamic Contrast-Enhanced MRI and Dynamic 18F-FDG-PET. Clinical Colorectal Cancer, 2011, 10, E1-E5.	2.3	16
157	F-18 FDG PET/CT as a Crucial Guide Toward Optimal Treatment Planning in a Case of Postirradiation Sarcoma 10 Years After Primary Bone Lymphoma of the Pelvis. Clinical Nuclear Medicine, 2011, 36, 565-567.	1.3	1
158	Scintigraphic Techniques for Early Detection of Cancer Treatment-Induced Cardiotoxicity. Journal of Nuclear Medicine, 2011, 52, 560-571.	5.0	92
159	Poster walks. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 229-259.	6.4	1
160	The role of [¹⁸ F]â€²-fluoroâ€²-deoxyâ€²-glucoseâ€²-positron emission tomography in thyroid nodules with indeterminate fineâ€²needle aspiration biopsy. Cancer, 2011, 117, 4582-4594.	4.1	79
161	Clinical applications of positron emission tomography in sarcoma management. Expert Review of Anticancer Therapy, 2011, 11, 195-204.	2.4	22
162	Shortened Dynamic ¹⁸ F-FDG PET. Journal of Nuclear Medicine, 2011, 52, 1330.1-1330.	5.0	1

#	ARTICLE	IF	CITATIONS
163	Malignant Transformation in an Area With Elevated F-18 FDG Uptake Within a Low Metabolic Benign Neurofibroma. <i>Clinical Nuclear Medicine</i> , 2010, 35, 271-272.	1.3	0
164	Nodular Fasciitis on F-18 FDG PET. <i>Clinical Nuclear Medicine</i> , 2010, 35, 830-831.	1.3	8
165	Methodological considerations in quantification of oncological FDG PET studies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1408-1425.	6.4	108
166	The role of 18F-FDG PET in the differentiation between lung metastases and synchronous second primary lung tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 2037-2047.	6.4	45
167	Metastasized Medullary Thyroid Carcinoma: Detection and Therapy Using Radiolabeled Gastrin Analogs. , 2010, , 416-432.		0
168	A Curve-Fitting Approach to Estimate the Arterial Plasma Input Function for the Assessment of Glucose Metabolic Rate and Response to Treatment. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1933-1939.	5.0	68
169	Postural Headache in Marfan Syndrome Associated with Spinal Cysts and Liquor Hypotension. <i>Neuropediatrics</i> , 2009, 40, 201-204.	0.6	15
170	Chemotherapy Response Monitoring of Colorectal Liver Metastases by Dynamic Gd-DTPA-Enhanced MRI Perfusion Parameters and 18F-FDG PET Metabolic Rate. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1777-1784.	5.0	29
171	2101 Evaluation of neoadjuvant chemotherapy with FDG PET/CT and MRI in adult patients with Ewing's sarcoma (ES) and osteosarcoma (OS): beyond RECIST. <i>European Journal of Cancer, Supplement</i> , 2009, 7, 168.	2.2	0
172	Monitoring and Predicting Response to Therapy with ¹⁸ F-FDG PET in Colorectal Cancer: A Systematic Review. <i>Journal of Nuclear Medicine</i> , 2009, 50, 43S-54S.	5.0	197
173	Evaluation of different normalization procedures for the calculation of the standardized uptake value in therapy response monitoring studies. <i>Nuclear Medicine Communications</i> , 2009, 30, 550-557.	1.1	16
174	Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. <i>Annals of Oncology</i> , 2008, 19, 348-352.	1.2	98
175	Comparison of Tumor Volumes Derived from Glucose Metabolic Rate Maps and SUV Maps in Dynamic ¹⁸ F-FDG PET. <i>Journal of Nuclear Medicine</i> , 2008, 49, 892-898.	5.0	51
176	Shortened dynamic FDG-PET protocol to determine the glucose metabolic rate in non-small cell lung carcinoma. , 2008, , .		7
177	Predictive and prognostic value of FDG-PET. <i>Cancer Imaging</i> , 2008, 8, 70-80.	2.8	52
178	Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1592-1598.	5.0	109
179	Biological correlates of FDG uptake in non-small cell lung cancer. <i>Lung Cancer</i> , 2007, 55, 79-87.	2.0	174
180	Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer. <i>Cancer</i> , 2007, 110, 1654-1664.	4.1	141

#	ARTICLE	IF	CITATIONS
181	A prospective multi-centre study of the value of FDG-PET as part of a structured diagnostic protocol in patients with fever of unknown origin. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 694-703.	6.4	182
182	Effects of hyperoxygenation on FDG-uptake in head-and-neck cancer. Radiotherapy and Oncology, 2006, 80, 51-56.	0.6	7
183	FDG-PET in colorectal cancer. Cancer Imaging, 2006, 6, S71-S81.	2.8	41
184	Scintigraphic imaging of P-glycoprotein expression with a radiolabelled antibody. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 1266-1272.	6.4	6
185	FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma. Annals of Oncology, 2006, 17, 1650-1655.	1.2	48
186	18F-FDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results. Journal of Nuclear Medicine, 2006, 47, 770-5.	5.0	71
187	Comparison of image-derived and arterial input functions for estimating the rate of glucose metabolism in therapy-monitoring 18F-FDG PET studies. Journal of Nuclear Medicine, 2006, 47, 945-9.	5.0	70
188	Decrease in circulating anti-angiogenic factors (angiostatin and endostatin) after surgical removal of primary colorectal carcinoma coincides with increased metabolic activity of liver metastases. Surgery, 2005, 137, 246-249.	1.9	52
189	Gadopentetate Dimeglumine and FDG Uptake in Liver Metastases of Colorectal Carcinoma as Determined with MR Imaging and PET. Radiology, 2005, 237, 181-188.	7.3	20
190	Tracers to Monitor the Response to Chemotherapy: In Vitro Screening of Four Radiopharmaceuticals. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 457-465.	1.0	2
191	Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 768-774.	6.4	49
192	The role of ¹⁸ F-fluoro-2-deoxyglucose positron emission tomography in initial staging and restaging after chemotherapy for testicular germ cell tumours. BJU International, 2002, 89, 549-556.	2.5	135
193	Gastroesophageal Reflux and Myocardial Imaging. Clinical Nuclear Medicine, 2000, 25, 834.	1.3	0